Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Systematic Review of Intramedullary Metastases in Breast Cancer
Neuro-oncology
P07 - (-)
015
BACKGROUND: Breast cancer is the second most common cause of intramedullary metastases. Progressive neurologic disability often results. The prognosis is generally poor. A comprehensive review of this subject has not been published previously.
DESIGN/METHODS: This systematic literature search used Pubmed and Yale library search engines. A total of 34 publications were found, encompassing 297 patients with IMM from which 87(29.29%) had metastasis from breast cancer.
RESULTS: The mean age of the patients was 50.5 years (range 42-66). Of 52 patients where the location of the tumor was defined, 46 (88.5%) were solitary. The location of the lesion was cervical in 20, thoracic in 13, thoracolumbar in 3 and lumbar in 11 patients. Concurrent brain metastesis was present in 37(42.5%) patients. The most common symptoms were weakness in 21(24%), sensory loss 15(17%), neck or back pain 18(21%) and urinary incontinence 12(14%). In 17 patients cerebrospinal fluid (CSF) findings were reported had elevated protein (mean 182.25 mg/dl; range 66-342 mg/dl). One patient had malignant cells in CSF. The interval from diagnosis of breast cancer to IMM ranged from 9-96 months (mean 48 months) and survival ranged from 2.5- 44 months (mean 14). Tumor markers; ER, PR and HER2 were reported in 8 patients. Local radiation, surgical resection, stereotactic radiosurgery and medical therapy were all applied in treatment.
CONCLUSIONS: Breast cancer comprises approximately one third of all intramedullary metastasis . Presence of brain and systemic metastasis as well as size of intramedullary tumor correlate with less favorable prognosis. The data on tumor markers is still insufficient for prognostication .
Authors/Disclosures
Rezvan Rostami, MD (Yale University School of Medicine)
PRESENTER 		No disclosure on file
Shivam O. Mittal, MD, FÂ鶹´«Ã½Ó³»­ (Cleveland Clinic Abu Dhabi) Dr. Mittal has nothing to disclose.
No disclosure on file
Bahman Jabbari, MD, FÂ鶹´«Ã½Ó³»­ Dr. Jabbari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Jabbari has received publishing royalties from a publication relating to health care.
Volker A. Knappertz, MD (Lacum Neurology) Dr. Knappertz has received personal compensation for serving as an employee of Noema Pharmaceuticals . Dr. Knappertz has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Sutura Pharmaceutical . Dr. Knappertz has received intellectual property interests from a discovery or technology relating to health care.